Support comes from new and existing investors, including life science, technology, growth, and sovereign wealth investors; Financing closely follows announcements of Iambic’s clinical data for IAM1363 at the ESMO Congress and entry into a clinical collaboration with Jazz Pharmaceuticals.
The company’s transformer model interprets up to one billion DNA fragments in each blood sample, capturing molecular context at a scale hundreds of times greater than leading LLMs and demonstrating strong clinical validation. With $6.7 million seed led by Felicis Ventures and Illumina Ventures, Hepta advances liquid biopsy platforms beyond oncology.
Spotlight on Tom Willis, PhD – CEO Arima Genomics
Spotlight on Abhijit “Ron” Mazumder, Ph.D. - Partner Illumina Ventures
Your screen does not meet the requirements for generating previews. Adjust your screen width to exactly 1920px before proceeding, otherwise you'll not be able to generate previews.
